For research use only. Not for human or veterinary use. Not for diagnostic or therapeutic use.
Menu
Reconstitution calculator

GH secretagogue

Ipamorelin Dosage, Protocol & Research Guide

By Sam, MBA

  • MW 711.9 g/mol
  • CAS 170851-70-4
Dosage, protocol, reconstitution and storage reference for Ipamorelin, with a reconstitution calculator, vial sizes and cited research.

Dose overview

Every range below is taken from the cited source and carries its evidence grade.

Human data and community reports

Human data and community reports
SourcePopulationDoseFrequencyRouteDurationEvidence
Human clinical trial[3]humanadults undergoing small or large bowel resection (hospital inpatients; 117 enrolled), phase 2 trial0.03 mg/kg[3]intravenous, dose per infusion, given twice daily from postoperative day 1 to day 7 or dischargetwice dailyintravenous— Human clinical trialStudy details from the source: Phase 2 randomized double-blind placebo-controlled trial in bowel-resection patients (Int J Colorectal Dis 2014, doi 10.1007/s00384-014-2030-8; NCT00672074): intravenous infusions of ipamorelin 0.03 mg/kg versus placebo twice daily from postoperative day 1 to day 7 or hospital discharge

Evidence grades: A approved label, B human trial, C observational, D animal study, E community-reported.

Reconstitution calculator

Sizes in published sources5 mg10 mg

Calculator example, not a recommended amount

Concentration
2.5 mg/mL
Volume to draw
0.1 mL
Units on a U-100 syringe
10 units

0102030405060708090100

Properties

CAS
170851-70-4
Molecular weight
711.9 g/mol
Formula
Not yet recorded
Sequence
Aib-His-D-2Nal-D-Phe-Lys-NH2
Aliases
NNC 26-0161
Vial sizes (mg)
5, 10

Study duration

1 week[3] Human trial

Duration of the cited study. It describes the source and is not a recommended cycle; no off period is stated. Source

Storage

Lyophilised (dry powder)

-20 °C; supplied as a solid (Cayman Chemical Ipamorelin (acetate), item 39813); shipped at room temperature in the continental US.[4]

Source

Storage notes

Lyophilized
Not yet recorded from a cited source
Reconstituted stability (days)
Not yet recorded from a cited source

Side effects, contraindications and regulatory status

Reported side effects

  • Phase 2 trial, 114 analysed bowel-resection patients, ipamorelin 0.03 mg/kg intravenous twice daily for up to 7 days: any emergent adverse event in 87.5% of ipamorelin vs 94.8% of placebo patients; the authors report it was well tolerated (Beck 2014). Intravenous, hospital.[3] Human trial
  • FDA safety-risk page (503B category 2, added 2023-09-29): a published study identified serious adverse events including death when ipamorelin was given intravenously for gastric motility; FDA identified no safety information for other injectable routes.[2] Regulator or expert-panel statement

Regulatory status

Ipamorelin acetate is in FDA 503B category 2 (added 2023-09-29) and also in the 'nominated but withdrawn' table of the FDA safety-risk page (current 2026-04-22); no US label. Checked 2026-10-20.[2] Source

Report any adverse reaction to a qualified healthcare professional.

What the research says

Summaries of the cited studies, each with its evidence grade.

  • pubmed.ncbi.nlm.nih.gov[3]

    Human trial human

    Phase 2 randomized double-blind placebo-controlled trial in bowel-resection patients (Int J Colorectal Dis 2014, doi 10.1007/s00384-014-2030-8; NCT00672074): intravenous infusions of ipamorelin 0.03 mg/kg versus placebo twice daily from postoperative day 1 to day 7 or hospital discharge

    Human clinical trial

  • Dose-escalation PK/PD study in healthy male volunteers (Pharm Res 1999, doi 10.1023/a[1]

    Human trial human

    Dose-escalation PK/PD study in healthy male volunteers (Pharm Res 1999, doi 10.1023/a:1018955126402): intravenous infusion over 15 minutes at 4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg, eight subjects per dose level

    Human clinical trial

Frequently asked questions

What dose figures are published for Ipamorelin?

Cited figures on this page: 0.03 mg/kg twice daily, intravenous, dose per infusion, given twice daily from postoperative day 1 to day 7 or discharge [3] (Human clinical trial, evidence grade B). These are summaries of published sources, not medical advice. Each figure links to its source in the references.

How is lyophilised Ipamorelin stored?

Cited storage for the lyophilised vial: -20 °C; supplied as a solid (Cayman Chemical Ipamorelin (acetate), item 39813); shipped at room temperature in the continental US..

What study duration is cited for Ipamorelin?

The cited duration is 1 week, with no off period stated (Human clinical trial). It describes the source, not a recommendation.

What is the regulatory status of Ipamorelin?

Ipamorelin acetate is in FDA 503B category 2 (added 2023-09-29) and also in the 'nominated but withdrawn' table of the FDA safety-risk page (current 2026-04-22); no US label. Checked 2026-10-20.

Compound facts

Recorded molecular weight: 711.9 g/mol.
Recorded CAS number: 170851-70-4
Not yet recorded from a cited source.

Sources

https://pubchem.ncbi.nlm.nih.gov/compound/9831659
PubMed IDs
10496658, 9849822

References

Numbered sources used on this page. Markers in the text link here.

  1. Dose-escalation PK/PD study in healthy male volunteers (Pharm Res 1999, doi 10.1023/a pubmed.ncbi.nlm.nih.gov Human trial
  2. fda.gov Regulator or expert-panel statement
  3. pubmed.ncbi.nlm.nih.gov Human trial
  4. caymanchem.com Manufacturer documentation